Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy

被引:13
|
作者
Neubecker, Katherine [1 ]
Adams-Huet, Beverley [2 ]
Farukhi, Irfan M. [3 ]
Delapena, Rosinda C. [3 ]
Gruntmanis, Ugis [4 ,5 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Dallas Vet Affairs Med Ctr, Dept Nucl Med, Dallas, TX 75216 USA
[4] Dallas Vet Affairs Med Ctr, Dept Med, Dallas, TX 75216 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75216 USA
关键词
D O I
10.4061/2011/924595
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Decrease of bonemineral density (BMD) and fracture risk is increased in men with prostate cancer receiving androgen deprivation therapy (ADT). We looked at possible predictors of decreased BMD and increased fracture risk in men with prostate cancer; most of whom were on ADT. In a retrospective study, we analyzed serum, BMD, and clinical risk factors used in the Fracture Risk Assessment (FRAX) tool and others in 78 men with prostate cancer with reported height loss. The subjects were divided in two groups: 22 men with and 56 without vertebral fractures. 17 of the 22 men with vertebral fractures on spine X-rays did not know they had a vertebral fracture. Of those 17 men, 9 had not previously qualified for treatment based on preradiograph FRAX score calculated with BMD, and 6 based on FRAX calculated without BMD. Performing spine films increased the predictive ability of FRAX for vertebral fracture. Vertebral fracture was better predicted by FRAX for other osteoporotic fractures than FRAX for hip fractures. The inclusion of BMD in FRAX calculations did not affect the predictive ability of FRAX. The PSA level showed a positive correlation with lumbar spine BMD and accounted for about 9% of spine BMD.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer
    Vahakn B. Shahinian
    Yong-Fang Kuo
    Journal of General Internal Medicine, 2013, 28 : 1440 - 1446
  • [22] Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer
    Shahinian, Vahakn B.
    Kuo, Yong-Fang
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 (11) : 1440 - 1446
  • [23] Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation Therapy
    James, Herbert, III
    Aleksic, Ilija
    Bienz, Marc Nicolas
    Pieczonka, Christopher
    Iannotta, Peter
    Albala, David
    Mariados, Neil
    Mouraviev, Vladimir
    Saad, Fred
    UROLOGY, 2014, 84 (01) : 164 - 168
  • [24] Fracture risk assessment of men treated with androgen deprivation therapy for prostate cancer
    Turo, R.
    Smolski, M.
    Das, S.
    Awsare, N. S.
    Pettersson, B. A.
    Adeyoju, A.
    Bromage, S. J.
    Brown, S. C. W.
    Brough, R.
    Collins, G. N.
    BJU INTERNATIONAL, 2016, 118 : 29 - 29
  • [25] Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
    R B Egerdie
    F Saad
    M R Smith
    T L J Tammela
    J Heracek
    P Sieber
    C Ke
    B Leder
    R Dansey
    C Goessl
    Prostate Cancer and Prostatic Diseases, 2012, 15 : 308 - 312
  • [26] Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
    Smith, M. R.
    Chu, F.
    Forrest, J.
    Malkowicz, S. B.
    Price, D.
    Sieber, P.
    Barnette, K. G.
    Segal, S.
    Steiner, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 229S - 229S
  • [27] Management of decreased bone mineral density (BMD) in men starting androgen deprivation therapy (ADT) for prostate cancer
    Panju, A. H.
    Breunis, H.
    Cheung, A. M.
    Duff-Canning, S.
    Fleshner, N. E.
    Krahn, M.
    Naglie, G.
    Tomlinson, G.
    Warde, P.
    Alibhai, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] A RESPONDER ANALYSIS OF THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY
    Egerdie, Blair
    Smith, Matthew R.
    Tammela, Teuvo L. J.
    Saad, Fred
    Ke, Chunlei
    Goessl, Carsten
    Dansey, Roger
    JOURNAL OF UROLOGY, 2009, 181 (04): : 611 - 611
  • [29] Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
    Egerdie, R. B.
    Saad, F.
    Smith, M. R.
    Tammela, T. L. J.
    Heracek, J.
    Sieber, P.
    Ke, C.
    Leder, B.
    Dansey, R.
    Goessl, C.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (03) : 308 - 312
  • [30] Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy
    S Yaturu
    S DjeDjos
    G Alferos
    C Deprisco
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 35 - 38